Xeljanz is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Xeljanz is the first oral therapy to be FDA-approved for the treatment of moderately to severely active UC.
If you have a Hayes login, click here to view the full report on the Knowledge Center.